RORγT agonists as immune modulators in anticancer therapy.

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Retinoid-related Orphan Receptor gamma t (RORγT) is a transcription factor crucial for Th17 lymphocyte development and IL-17-expressing cells.
• These RORγT-expressing cells play roles in host defense, autoimmune diseases, and cancer immunity.
• RORγT activity is modulated by small-molecule ligands, with a focus on inverse agonists for autoimmune conditions.

Purpose of the Study:

• To highlight the overlooked potential of RORγT agonists in therapeutic applications.
• To review recent advancements in the biology of RORγT agonists.
• To explore the application of RORγT agonists in anticancer therapy.

Main Methods:

• Review of existing literature on RORγT biology and ligand development.
• Analysis of studies investigating the role of RORγT-expressing cells in cancer immunity.
• Synthesis of recent findings on RORγT agonists and their mechanisms.

Main Results:

• RORγT agonists can stimulate Th17 and Tc17 lymphocytes, enhancing anti-tumor immune responses.
• The development of RORγT agonists has been less explored compared to inverse agonists.
• Recent research provides insights into the biological activities and therapeutic potential of RORγT agonists.

Conclusions:

• RORγT agonists represent a promising therapeutic strategy for cancer treatment by boosting anti-tumor immunity.
• Further research into RORγT agonists is warranted to fully exploit their potential in oncology.
• This review emphasizes the dual role of RORγT modulation in autoimmune diseases and cancer.